Drug Profile
Research programme: autoimmune and inflammatory disorder therapies - Sienna Biopharmaceuticals
Alternative Names: CT637; CT802Latest Information Update: 16 Dec 2016
Price :
$50
*
At a glance
- Originator Creabilis Therapeutics
- Class
- Mechanism of Action High mobility group protein modulators; Toll-like receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation; Plaque psoriasis; Rheumatoid arthritis; Skin disorders
Most Recent Events
- 06 Dec 2016 Creabilis Therapeutics has been acquired by Sienna Biopharmaceuticals
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Italy
- 16 Jul 2016 No recent reports of development identified for preclinical development in Plaque-psoriasis in Italy (Topical)